Insmed INSM Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 313.8%+6.0pp | 308.5%-0.9pp | 305.2%-6.3pp | 305.9%-6.9pp | 307.8%-6.2pp | |
| Operating margin | -857.5%+114pp | -974.4%-36.5pp | -1,010.2%-81.4pp | -992.2%-61.1pp | -971.2%-25.4pp | |
| Net margin | -879.6%+134pp | -1,001.1%-16.9pp | -1,041.8%-63.2pp | -1,029%-44.7pp | -1,013.4%-15.2pp | |
| EBITDA margin | -846.4%+113pp | -962.5%-35.3pp | -998.1%-78.6pp | -980.3%-57.6pp | -959.8%-22.1pp | |
| Free cash flow margin | -692.9%+73.5pp | -787.6%-41.8pp | -822.1%-90.3pp | -804.8%-71.7pp | -766.4%-36.5pp | |
| Returns | ||||||
| Return on equity | -870%— | —— | —— | —— | —— | |
| Return on assets | -222.4%+1.0pp | -229.8%-19.0pp | -224.8%-18.2pp | -222.3%-4.5pp | -223.5%+0.8pp | |
| Return on invested capital | -766%+39.9pp | -814.9%+233pp | -806.4%+347pp | -816.1%+392pp | -805.9%+198pp | |
| Efficiency | ||||||
| Asset turnover | 1.1×+0.2× | 0.9×+0.1× | 0.9×0.0× | 0.9×0.0× | 0.9×0.0× | |
| Inventory turnover | 4.3×+0.6× | 4×+0.4× | 3.9×+0.3× | 3.8×+0.3× | 3.7×+0.3× | |
| Liquidity | ||||||
| Current ratio | 19.6×-0.8× | 21×+4.7× | 22.6×+7.6× | 24.4×+11.0× | 20.4×+4.6× | |
| Quick ratio | 18.3×-0.8× | 19.7×+4.4× | 21.2×+7.4× | 22.9×+10.7× | 19.1×+4.6× | |
| Cash ratio | 7.6×-0.1× | 7.7×+0.3× | 8.5×+0.8× | 9.5×+1.0× | 7.7×-1.3× | |
| Leverage | ||||||
| Debt-to-equity | 2.7×-46.3× | 13.4×— | 16.6×— | 18.1×— | 49×— | |
| Debt-to-assets | 1×-1.3× | 1.4×-1.4× | 1.7×-1.4× | 1.9×-1.6× | 2.4×-1.3× | |
| Interest coverage | -54.3×-13.5× | -51.8×-14.0× | -47.2×-11.1× | -43.4×-8.2× | -40.8×-3.7× | |
| Per Share | ||||||
| Book value per share | $18.05+239% | $15.33+833% | $13.36+643% | $11.67+261% | $5.32+162% | |
| Valuation | ||||||
| Market capitalization | $122.92B+159% | $101.48B+170% | $76.72B+159% | $57.57B+162% | $47.4B+215% | |
| Enterprise value | $122.53B+149% | $101.83B+160% | $77.59B+146% | $58.74B+145% | $49.25B+179% | |
| Price / sales | 222.8×+89.4× | 216.1×+106× | 188.8×+98.5× | 153.7×+83.4× | 133.4×+82.2× | |
| Price / book | 148.5×-314× | 237.8×— | 230.8×— | 222×— | 462.1×— | |
| EV / sales | 221.7×+83.3× | 216.9×+102× | 191.2×+95.0× | 157×+80.0× | 138.5×+78.3× | |
| Free cash flow yield | -12.5%+10.5pp | -15.6%+16.6pp | -18.7%+20.1pp | -21.4%+26.3pp | -23%+34.5pp | |
| Earnings yield | -15.8%+14.6pp | -19.8%+22.3pp | -23.8%+27.7pp | -27.5%+36.3pp | -30.5%+48.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insmed's profit margins?
- Insmed (INSM) runs a 81.8% gross margin and a -140.6% operating margin, with a -144.4% net margin.
- Where do Insmed's ratios come from?
- Every ratio is computed from Insmed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
